OncoSil secures FDA approval for targeted bile duct cancer device

OncoSil Medical received FDA approval under the Humanitarian Device Exemption for its OncoSil device to treat unresectable, non-metastatic distal cholangiocarcinoma, enabling market entry in the US with a limited initial commercial rollout.

This Wire brief sits within Fusion42's coverage of Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.